AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
acetohydroxamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 58 | 546-88-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
urease inhibitor
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.75 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 55 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.079 | High | 1 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 2.280 | High | 1 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 12.190 | 10^-6 cm/s | High | 1 |
| dh-clint | Dog hepatocyte intrinsic clearance | 2.472 | uL/min/10^6 cells | High | 1 |
| dppb | Dog plasma protein binding (% unbound) | 78.290 | % | High | 1 |
| herg | hERG pIC50 | 3.768 | pIC50 | High | 1 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 83.400 | % | High | 1 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.667 | uL/min/10^6 cells | High | 1 |
| hlm-clint | Human liver microsomal intrinsic clearance | 3.221 | uL/min/mg protein | High | 1 |
| hppb | Human plasma protein binding (% unbound) | 68.030 | % | High | 1 |
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,MTOR,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 55 | |||
| kinase-selectivity-class | AXL,BMX,CDK9,DYRK1A,GRK2,IRAK3,MAP2K6,STK33,TEK,TGFBR1 | 10 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.838 | High | 1 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 30.479 | High | 1 | |
| mppb | Mouse plasma protein binding (% unbound) | 97.140 | High | 1 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 7.762 | High | 1 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 92.980 | % | High | 1 |
| rh-clint | Rat hepatocyte intrinsic clearance | 3.758 | uL/min/10^6 cells | High | 1 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 98.980 | % | High | 1 |
| rppb | Rat plasma protein binding (% unbound) | 90.420 | % | High | 1 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 511.682 | uM | High | 1 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| May 31, 1983 | FDA | MISSION PHARMA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G04BX03 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Other urologicals |
| FDA MoA | N0000175087 | Urease Inhibitors |
| MeSH PA | D004791 | Enzyme Inhibitors |
| FDA EPC | N0000175611 | Urease Inhibitor |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:50635 | EC 3.5.1.5 (urease) inhibitor |
| CHEBI has role | CHEBI:84735 | algal metabolite |
Related Drugs by ATC class:
G04BX Other urologicals 10 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Urinary tract infectious disease | indication | 68566005 | |
| Struvite Renal Calculi | indication | ||
| Alcoholism | contraindication | 7200002 | |
| Acute nephropathy | contraindication | 58574008 | |
| Hemolytic anemia | contraindication | 61261009 | DOID:583 |
| Phlebitis | contraindication | 61599003 | DOID:864 |
| Leukopenia | contraindication | 84828003 | DOID:615 |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.38 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 2 | Enzyme | IC50 | 4.33 | CHEMBL | |||||
| Bacterial urease | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Urease | Enzyme | IC50 | 4.76 | CHEMBL | |||||
| Urease subunit beta | Enzyme | IC50 | 4.76 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4RZ82L2GY5 | UNII |
| 4018901 | VUID |
| N0000147195 | NUI |
| D00220 | KEGG_DRUG |
| 16728 | RXNORM |
| C0050451 | UMLSCUI |
| CHEBI:27777 | CHEBI |
| HAE | PDB_CHEM_ID |
| CHEMBL734 | ChEMBL_ID |
| 1990 | PUBCHEM_CID |
| DB00551 | DRUGBANK_ID |
| 5491 | INN_ID |
| C006358 | MESH_SUPPLEMENTAL_RECORD_UI |
| 4124 | MMSL |
| d01433 | MMSL |
| 4018901 | VANDF |
| 001242 | NDDF |
| 387426003 | SNOMEDCT_US |
| 74819009 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Lithostat | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0178-0500 | TABLET | 250 mg | ORAL | NDA | 18 sections |